<DOC>
	<DOCNO>NCT01143818</DOCNO>
	<brief_summary>Observational study AndroGel® , Testosterone 1 % gel therapy ( ESPRIT ) hypogonadal men community 6 month .</brief_summary>
	<brief_title>ESPRIT Study Hypogonadal Men</brief_title>
	<detailed_description>The objective study evaluate efficacy safety AndroGel ( testosterone gel ) 1 % follow administration community dwell men hypogonadism . The percent change baseline Month 6 age male symptom ( AMS ) assessment primary endpoint . Secondary endpoint change baseline Month 6 International Index Erectile Dysfunction ( IIEF ) , Multidimensional Fatigue Inventory ( MFI ) , body mass index ( BMI ) assessment .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria 1 . Male patient &gt; = 18 year age 2 . Hypogonadism previously treat testosterone 3 . Testosterone deficiency confirm clinically biochemically 4 . Being prescribe AndroGel® 1 % accordance local summary product characteristic Exclusion Criteria 1 . According contraindication , 2 . Unwilling unable sign inform consent form</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Male hypogonadism</keyword>
</DOC>